AstraZeneca PLC (AZN) stock
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
Earnings
AstraZeneca's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of AstraZeneca's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
AstraZeneca has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When AstraZeneca puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases AstraZeneca filed with the SEC as exhibits to Form 8-K or 6-K